ABX-1431 clinical trials
Also written ABX-1431.
- studies test it
- 15
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses ABX-1431 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
15 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Studies
Open first, then newest update. How each study uses ABX-1431 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)CompletedPhase 1H. Lundbeck A/SNCT04597450Written as Lu AG06466How we know
- A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple SclerosisTerminatedPhase 1H. Lundbeck A/SNCT04990219Written as Lu AG06466How we know
- A Study of Lu AG06466 in Participants With Treatment Resistant Focal EpilepsyTerminatedPhase 1H. Lundbeck A/SNCT05081518Written as Lu AG06466How we know
- Binding and Effects of Lu AG06466 in the Brain of Healthy MenCompletedPhase 1H. Lundbeck A/SNCT05219838Written as Lu AG06466How we know
- Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian ParticipantsTerminatedPhase 1H. Lundbeck A/SNCT05177029Written as Lu AG06466How we know
- A Study to Evaluate Lu AG06466 in Participants With FibromyalgiaTerminatedPhase 1H. Lundbeck A/SNCT04974359Written as Lu AG06466How we know
- Drug Drug Interaction Study With Lu AG06466 in Young Healthy MenCompletedPhase 1H. Lundbeck A/SNCT04713254Written as Lu AG06466How we know
- Binding of Lu AG06466 in the Brain in Healthy MenCompletedPhase 1H. Lundbeck A/SNCT04419636Written as Lu AG06466How we know
- Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and WomenCompletedPhase 1H. Lundbeck A/SNCT04405323Written as Lu AG06466How we know
- Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic DisorderCompletedPhase 2Abide TherapeuticsNCT03625453Written as ABX-1431How we know
- Titration Study of ABX-1431CompletedPhase 1Abide TherapeuticsNCT03447756Written as ABX-1431How we know
- Central Pain Study for ABX-1431CompletedPhase 1Abide TherapeuticsNCT03138421Written as ABX-1431 HClHow we know
- An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural CorrelatesCompletedPhase 1Abide TherapeuticsNCT02929264Written as ABX-1431How we know
- A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette SyndromeCompletedPhase 1Abide TherapeuticsNCT03058562Written as ABX-1431How we know
- A Study to Evaluate the Effects of ABX-1431 on Patients With Functional DyspepsiaTerminatedPhase 1Abide TherapeuticsNCT02875678Written as ABX-1431How we know